A number of risk scores already exist to predict cardiovascular (CV) events. However, scores developed with data collected some time ago might not accurately predict the CV risk of contemporary hypertensive patients that benefit from more modern treatments and management. Using data from the randomised clinical trial Anglo-Scandinavian Cardiac Outcomes Trial-BPLA, with 15 955 hypertensive patients without previous CV disease receiving contemporary preventive CV management, we developed a new risk score predicting the 5-year risk of a first CV event (CV death, myocardial infarction or stroke). Cox proportional hazard models were used to develop a risk equation from baseline predictors. The final risk model (ASCORE) included age, sex, smoking, diabetes, previous blood pressure (BP) treatment, systolic BP, total cholesterol, high-density lipoprotein-cholesterol, fasting glucose and creatinine baseline variables. A simplified model (ASCORE-S) excluding laboratory variables was also derived. Both models showed very good internal validity. User-friendly integer score tables are reported for both models. Applying the latest Framingham risk score to our data significantly overpredicted the observed 5-year risk of the composite CV outcome. We conclude that risk scores derived using older databases (such as Framingham) may overestimate the CV risk of patients receiving current BP treatments; therefore, 'updated' risk scores are needed for current patients.
INTRODUCTION
National and international guidelines increasingly recommend that the management of cardiovascular (CV) risk factors be influenced by estimated overall CV risk rather than the absolute values of any individual risk factor. 1, 2 Several risk scores or charts, many of which are based on the Framingham database, are currently available, 2-8 but most are not applicable solely to hypertensive patients who may subsequently receive and may already be taking contemporary treatment for hypertension. One score that is applicable to treated hypertensive patients-the INDANA score 5 -was based on trial data collated between 15 and 30 years ago, and included patients who already had established vascular disease, a population for whom risk assessment is not currently recommended. Two decades ago, rates of CV outcomes among treated hypertensive patients were significantly higher than currently treated patients who are exposed to greater concomitant use of other CV protective agents-particularly statins, 9 and are exposed to more assertive blood pressure (BP) lowering. 10 Hence, risk scores like INDANA developed on the basis of trials carried out 20 years ago are unlikely to be accurate when applied to current populations. Similarly, the latest Framingham risk score, 7 which includes antihypertensive treatment as a risk factor, is based on data collected over an extended period (eligible patients were identified at examination cycles from 1968 to 1987, with a maximum of follow-up period of 12 years). The more recent QRISK score 8 does include antihypertensive treatment at study entry as a risk factor, but was not developed specifically for use in hypertensive patients on treatment for hypertension, and its inclusion of a variable on area deprivation specific to the United Kingdom may make it less applicable to populations outside the United Kingdom.
Consequently, no risk chart is currently ideal for the CV risk assessment in the context of contemporary primary prevention among hypertensive adults who subsequently receive and could already be taking contemporary treatment for hypertension. The BP-lowering arm of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT-BPLA), 11, 12 which included 19 257 patients with hypertension, provided the opportunity of developing such a score. The objective was to provide a score, which would be 'userfriendly' for general practitioners who may not have all the necessary information-such as laboratory tests-available to them at the time of assessment, but at the same time would be sufficiently accurate to guide practice.
MATERIALS AND METHODS
The design, conduct and results of the ASCOT-BPLA trial have been reported previously. 11, 12 Briefly, we recruited 19 257 patients between 1 February 1998 and May 2000, mainly from family practices in the United Kingdom, Ireland and the Nordic countries. Patients were randomised to either atenolol±bendroflumethiazide or amlodipine±perindopril antihypertensive treatment regimens. As part of a 2 Â 2 factorial trial, 10 305 ASCOT-BPLA patients were also randomised to the lipid-lowering arm of the study (ASCOT-LLA) in which atorvastatin 10 mg was compared with placebo. 11, 13 Study eligibility
Patients were eligible for the ASCOT-BPLA trial if they had either untreated hypertension (systolic BP (SBP)X160 mm Hg and/or diastolic BPX100 mm Hg), or treated hypertension with SBPX140 mm Hg and/or diastolic BPX90 mm Hg, and were aged 40-79 years with at least 3 of the following other CV risk factors: male sex, ageX55 years, microalbuminuria or proteinuria, smoking, total-to high-density lipoprotein-cholesterol ratioX6, family history of premature coronary heart disease, leftventricular hypertrophy, other specified abnormalities on electrocardiogram, type 2 diabetes mellitus, peripheral arterial disease, previous stroke or transient ischaemic attack. Patients were excluded from the trial if they had a previous history of myocardial infarction (MI), currently treated angina, a cerebrovascular event in the last 3 months, fasting triglyceride level44.5 mmol l À 1 , heart failure, uncontrolled arrhythmias or any clinically important haematological or biochemical abnormality on routine screening. The ASCOT-BPLA patients with previous CV disease at baseline were excluded for the analyses presented in this report.
Statistical methods
The primary composite end point used for the development of this risk prediction model was first CV death, MI (including silent) or stroke. In the ASCOT-BPLA patients, we estimated a predicted 5-year risk for this outcome using the latest Framingham risk model 7 and we compared it with the observed 5-year risk calculated using the Kaplan-Meier method. We then developed our own risk prediction model.
We identified a priori the baseline variables to be considered for inclusion in the risk score model; sex, age, race, smoking in the last 12 months, education, diabetes, previous antihypertensive treatment (within the last month), previous lipid-lowering treatment, aspirin treatment, SBP, diastolic BP, heart rate, height, weight, body mass index, microalbumina/ proteinuria, renal dysfunction, LVH, total cholesterol, high-density lipoprotein-cholesterol, fasting low-density lipoprotein-cholesterol, fasting triglyceride, fasting glucose, creatinine and estimated Glomerular Filtration Rate (eGFR) using the Modification of Diet Renal Disease Formula. 14 The risk score model ('ASCORE') was identified by fitting Cox proportional hazard models with a backward stepwise selection approach removing variables one by one. We opted to use a manual approach instead of a mathematical algorithm. A manual approach allows for inclusion of clinical and logical judgement, and for identification of confounding variables that may not be picked up by mathematical modelling. On several occasions, we have re-introduced variables that were removed earlier, to check if they now fitted the model better. Variables were included in the final model based on the strength of the relationship with the outcome and/or what was useful on a clinical basis. As 1975 patients had missing values of fasting glucose or creatinine in the final model, we performed a multiple imputation analysis, creating five imputed data sets and combining them using Rubin's rules 15 to obtain the model's coefficients. We also created a 'simplified' version of the risk score model ('ASCORE-S') by excluding laboratory measurement variables and re-estimating the coefficients of the remaining variables. We tested the proportional hazard assumption of the models graphically and using Schoenfield residuals. We also tested for non-linear effects of continuous variables using second and third power terms.
We converted the ASCORE and ASCORE-S models into 'user-friendly' integer scores for the 5-year risk of the primary composite end point by rounding the exact coefficients from the Cox models. We re-centred and coded variables so that a zero score (the 'baseline group') corresponded to an adult at clinically low risk (female, non-diabetic, non-smoker, no previous antihypertensive treatment, agep40 years, SBPp120 mm Hg, and additionally for ASCORE, total cholesterolp3.5 mmol l
). Each individual's score increases by an integer amount for each risk factor level above the lowest risk category, resulting in a total score for that individual. The estimated probability of CV death, MI or stroke within 5 years is then equal to (1-0.9985 exp(0.1*total score) ) for ASCORE and (1-0.9966 exp(0.1*total score) ) for ASCORE-S. The equations differ as the ASCORE-S baseline group includes patients with a range of values for the laboratory measurement variables, and hence, they are at greater risk than the ASCORE baseline group.
To assess model fit internally, we used a version of the HosmerLemeshow test 7, 16, 17 by comparing predicted and observed 5-year risks (estimated using the Kaplan-Meier method) in deciles of risk. To assess any gain in using the ASCORE model over the simplified ASCORE-S model, we compared the areas under the receiver-operating curves (ROC) and also tested the Net Reclassification Improvement suggested by Pencina et al. 18 To assess whether predictive power is lost by using integer scores rather than the exact coefficients of the Cox models, we compared areas under the ROC curves generated by predictions from these two methods. External validity will have to be tested on a different data set.
RESULTS
Of the 19 257 patients randomised into the ASCOT-BPLA trial, 3302 with previous CV disease at baseline were excluded, leaving 15 955 patients for analysis. Mean follow-up was 5.4 years (s.d. 1.2) and 1240 patients experienced a component of the primary composite end point of CV death, MI or stroke.
The latest Framingham model 7 predicted an average 5-year risk of 8.2% of having the outcome (95% confidence intervals (CIs) from 8.1-8.3%). Although the observed Kaplan-Meier 5-year risk in the data was 7.1%, the Hosmer-Lemeshow test using deciles of risk had a P-valueo0.00001 (see Figure 1) . Table 1 shows the estimated hazard ratios and 95% CIs for the full (ASCORE) and simplified (ASCORE-S) multivariable models. In ASCORE, male sex, age, diabetes, smoking in last 12 months, SBP, total cholesterol, high-density lipoprotein-cholesterol, fasting glucose and creatinine were found to be statistically significant predictors of the primary outcome. Previous antihypertensive treatment was not a statistically significant predictor, but was nevertheless included in the model for pragmatic clinical reasons. Statistically significant interactions were found between age and sex (interaction: P ¼ 0.006), and age and smoking status (interaction: P ¼ 0.011). The hazard ratio for diabetics versus non-diabetics was greater in females than in males, and the interaction, although not statistically significant, was retained in the model for its clinical interest. There was no evidence against the proportional hazards assumption or of non-linearity of continuous variables in the two final models. Table 2 shows the ASCORE integer risk score derived from the multivariable models (with modifications needed for ASCORE-S). 
The formulas in the methods section can be applied to convert an individual's total score to a 5-year risk of CV death, MI or stroke for both scores (see Supplementary Material S1).
The predicted 5-year risk of an event calculated using the simplified ASCORE-S can potentially change considerably when laboratory data are taken into account using the full ASCORE model (see figure in Supplementary Material S2). This is demonstrated for two 'extreme' individuals where the predicted 5-year risks change from 0.76 to 1.64% and from 18.58% to 10.47% on using ASCORE instead of ASCORE-S (Supplementary Material S3). However, large differences were infrequent with 90% of patients having a difference in risk estimates of o2% between the two scores (data not shown).
The predicted 5-year risks were very similar to the observed risks for both the ASCORE and ASCORE-S models (HosmerLemeshow test: P ¼ 0.22 and P ¼ 0.49, respectively; Figure 2 ). Although the ROC curves for ASCORE and ASCORE-S were also similar (see figure a in Supplementary Material S4), the larger area under the ROC curve (AUC) for ASCORE (0.664; 95% CI: 0.648-0.680) than for ASCORE-S (0.648; 95% CI: 0.631 to 0.664) suggests the full model is more powerful (w 2 -test comparing the two AUC: Po0.0001). Similarly, comparison of ASCORE and ASCORE-S by The effect of age depends on the gender and the smoking status of the person; hence, only one of the four rows applies to any specific person. Abbreviations: AHT, previous antihypertensive treatment; CV, cardiovascular; Diab, diabetic; Glucose, fasting glucose; HDL, high-density lipoproteincholesterol; MI, myocardial infarction; SBP, systolic blood pressure; TC, total cholesterol. a To calculate the total ASCORE score for a patient, ignore the numbers in the brackets, start with the score corresponding to the relevant combination of sex and age group (choose one number within the grey shaded area of the table). Next, add the corresponding points for diabetic status (by sex), smoking status (by age group) and previous antihypertensive treatment. For SBP and laboratory measures (ASCORE only), a scale of points from þ 1 to þ 8 is shown under which the values of the variable are given. If a patient has a value between two values in the table, the smaller of the two corresponding points should be added. To compute ASCORE-S, add the italic numbers in the brackets to the number to the left of the brackets in each cell before starting the computation. The estimated probability of CV death, MI or stroke within 5 years is then equal to (1-0.9985 exp(0.1*total score) ) for ASCORE and (1-0.9966 exp(0.1*total score) ) for ASCORE-S. The numbers 0.9985 and 0.9966 are the probability of not having an event in the baseline group individuals. These numbers can be recalculated for the specific population where the score is used as explained in the methods section. When computing ASCORE for a 54 year old male we start with 17 points and we will add þ 1 if he is diabetic and þ 2 if his blood pressure reaches 138. However, to compute ASCORE-S for the same patient we will start with 17 þ 1 ¼ 18 points and we will add þ 1 þ 2 ¼ þ 3 if he is diabetic and þ 2 if his blood pressure reaches 138 À 1 ¼ 137. The bold values represent points to be added to the score. . Considering all patients combined, ASCORE assigned a probability closer to the observed outcome of the patient than ASCORE-S in 59% of patients. The ROC curves for the ASCORE model using the exact coefficients (Table 1 ) and the integer scores (Table 2) were also very similar (AUC 0.666 (95% CI, 0.650-0.682) versus AUC 0.664 (95% CI, 0.648-0.680), respectively, P ¼ 0.09; see figure b in Supplementary Material S4). Therefore, although prediction is slightly worse for the integer scores than for the exact coefficients, the absolute differences are limited.
DISCUSSION
These analyses based on the database of a large contemporary randomised trial of almost 16 000 hypertensive patients with no history of CV disease have generated a risk score (ASCORE) and a simplified version of the same score (ASCORE-S). Both can be used to predict subsequent adverse CV events over the ensuing 5 years in hypertensive patients, whether currently on antihypertensive treatment or not. Despite entering 23 variables into the model, no innovative, rarely measured variables were considered-rather the two scores incorporate 10 and 6 variables, respectively, all of which are 'classic' risk factors. The ASCORE-S includes no laboratory variables, and as such allows the attending physician to make an initial CV assessment of a patient pending additional information that will allow further refinement. The internal validity of ASCORE had a good discrimination (AUC ¼ 0.664) and calibration ( Figure 2) . In contrast to ASCORE, the recent SCORE charts 6 were not designed for hypertensive patients on treatment for hypertension. The INDANA risk score 5 and the latest Framingham risk score, 7 which do include antihypertensive treatment (start of or current use at baseline, respectively) as one of the risk score factors, suffer from a lack of contemporary data. The relatively modern QRISK 8 score does include antihypertensive treatment at entry to the study as a risk factor, but was not developed solely for use in hypertensive patients. QRISK also includes a variable of area deprivation (the Townsend score) that is routinely collected in the United Kingdom, but may not be available in other countries. Consequently, the utility of most existing scores and charts are compromised, because they are not specifically tailored for hypertensive patients managed to contemporary standards. The use of the ASCOT-BPLA database to develop ASCORE and ASCORE-S is open to the criticism that the results lack generalisability to most hypertensive patients. However, the majority of patients in ASCOT were from family practices (with male sex, age455 and smoking as the three most common associated risk factors), and are fairly typical of hypertensive patients seen routinely. Even where ASCOT patients have different average levels of a variable compared with the general population (for example, cholesterol levels), as long as the 'biological effect' of these variables on risk does not differ in the two populations, the ASCORE model will correctly estimate the risk of the patient. A number of other risk scores are also derived from clinical trial data, such as the score for CV death derived from the INDANA 5 data set, the TIMI 19 score for unstable angina and the score for patients with stable angina derived from the ACTION trial. 20 Another potential criticism of ASCORE concerns the limited representation of ethnic minorities in ASCOT-BPLA. This is a common problem of many databases used to develop risk scores. In ASCOT, patients were randomised from eight countries from Northern Europe. This compares with the relatively small ethnically and socially homogenous Framingham population. 3, 7 The alternative would be to use data collected over a wider geographical area, and potentially from different populations. However, this usually requires combining data from different studies or data sources, leading to potentially serious problems with data coherence and quality.
In the ASCORE model, the 'previous antihypertensive treatment' variable had a negative impact on the predicted risk, as was also shown in other scores. 7, 8 The limited statistical impact of this variable in ASCORE and ASCORE-S may reflect the crude method of evaluation used-viz whether patients had been taking antihypertensive treatment within the month before screening for entry to the trial. Earlier treatment, or treatment between screening and trial inception could have affected associated outcomes.
Risk scores can be re-calibrated to account for their use in populations with differing underlying baseline CV risks. However, such recalibrations assume that the risk factor hazard ratios remain unchanged in the new population, which may not always be the case in the context of an earlier versus a contemporary cohort in which patient management has progressed substantially. Improved treatment and patient management means a more effective tackling of elevated risk factors at baseline (such as high lipids). This will be reflected in lower 'effects' (hazard ratios) of the baseline risk factors. Patients in more recent studies generally benefit from better treatment and, thus, models based on recent cohorts (such as ASCORE) should estimate lower hazard ratios for baseline variables than the models based on older cohorts (such as Framingham). Such disparity means that scores based on old cohorts tend to exaggerate risk when applied to contemporary cohorts, as we have found in our analysis where the Framingham model clearly overpredicted the risks in ASCOT-BPLA ASCORE: an up-to-date cardiovascular risk score D Prieto-Merino et al patients at high deciles of risk (Figure 1) . Unfortunately, we were unable to assess the QRISK score 8 in the ASCOT-BPLA patients owing to the lack of social deprivation variable 'Townsend score', which is used in QRISK.
In conclusion, it seems likely that the older scores derived from older databases become obsolete in a contemporary setting. ASCORE and ASCORE-S are critically based on data in the context of contemporary clinical practice. Both scores provide userfriendly, easy to use, accurate risk scores for estimating CV risk among patients with hypertension about to receive contemporary antihypertensive management, whether previously treated or not. As such, they represent a very useful tool for general physicians seeing routine hypertensive patients in the context of primary prevention.
What is already known about this topic
There are several risk scores for CV disease that tend to use similar risk factors. Many of these scores are based on relatively outdated cohorts. The effects (hazard ratios) of the risk factors in these scores are maybe too high, because the patients did not have the benefit of contemporary treatment when they were developed.
What this study adds A risk score with the usual risk factors, but based on a modern cohort so that the effects (hazard ratios) of the risk factors in this score do take into account modern treatment and patient management, and therefore tend to be smaller. A simplified version of the risk score that can be used when lab data is not available.
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